Importantly, the combination of β-lap with Poly(ADP-ribose) Polymerase 1 (PARP1) inhibitors induces a cell death mechanism switch from PARP1 hyperactivation-mediated programmed necrosis to synergistic tumor-selective, caspase-dependent apoptosis [9]. The gene discussed is PARP1; the disease is neoplasm.